Half-year report · Q2
3750.TEDINET S100US7P
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥91m | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥1.6bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥863m | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | −¥407m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | −¥354m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | −¥420m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥907m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥424m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥432m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥419m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥432m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥138m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥443m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥433m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | −¥443m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥5.1bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥5.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥13.6bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥2.8bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥3.0bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥2.3bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥2.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥2.2bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥522m | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥522m | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥208m | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥673m | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥421m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥367m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥8.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥102m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥7.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥94m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-48.42 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.47 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-49.65 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥15.42 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 41.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 14.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥144m |
| jpcrp040300-q2r_E05443-000Medical Asset Managemetreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥65m |
| jpcrp040300-q2r_E05443-000Medical Asset Managemetreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥65m |
| jpcrp040300-q2r_E05443-000Medical Asset Managemetreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥206m |
| jpcrp040300-q2r_E05443-000Real Asset Managementreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥27m |
| jpcrp040300-q2r_E05443-000Real Asset Managementreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥27m |
| jpcrp040300-q2r_E05443-000Real Asset Managementreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥57m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥91m |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥91m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | −¥263m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | −¥87m |
| jpcrp040300-q2r_E05443-000Medical Asset Managemetreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥45m |
| jpcrp040300-q2r_E05443-000Medical Asset Managemetreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥45m |
| jpcrp040300-q2r_E05443-000Medical Asset Managemetreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥285m |
| jpcrp040300-q2r_E05443-000Real Asset Managementreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥818m |
| jpcrp040300-q2r_E05443-000Real Asset Managementreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥818m |
| jpcrp040300-q2r_E05443-000Real Asset Managementreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥17m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥863m |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥863m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | −¥267m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 444
| Item | Context | Value | Unit |
|---|---|---|---|
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E05443 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 37500 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社サイトリ細胞研究所 | |
| Filer name in english | FilingDateInstant | Cytori Cell Research Institute,Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Current period end date | FilingDateInstant | 2024-09-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Comparative period end date | FilingDateInstant | 2023-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Material matters relating to going concern etc business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所（スタンダード市場） | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数は、100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)株式会社ＨＧキャピタル | |
| Address major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)大阪府大阪市中央区南船場２－12－16 | |
| Name major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)CIGメディカル投資事業有限責任組合 | |
| Address major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)東京都千代田区永田町２－11－１ | |
| Name major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)橋本 征道 | |
| Address major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)東京都港区 | |
| Name major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)株式会社東京ウエルズ |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |